当前位置: X-MOL 学术Pediatr. Nephrol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.
Pediatric Nephrology ( IF 2.6 ) Pub Date : 2018-12-12 , DOI: 10.1007/s00467-018-4154-5
Winnie Y Sohn 1 , Anthony A Portale 2 , Isidro B Salusky 3 , Hao Zhang 1 , Lucy L Yan 1 , Bella Ertik 1 , Shahnaz Shahinfar 4 , Edward Lee 1 , Bastian Dehmel 1 , Bradley A Warady 5
Affiliation  

The original version of this article unfortunately contained three mistakes. In Table 1, the last line under "Key Inclusion Criteria" should read "Normal or clinically acceptable ECGs at screening and at day - 1." In addition, the abbreviation "IP" in the legend to Table 1 stands for "investigational product."

中文翻译:

校正至:一项开放性单剂量研究,用于评估慢性肾病接受透析的28岁至6岁以下儿童受试者中西那卡塞的安全性,耐受性,药代动力学和药效学。

不幸的是,本文的原始版本包含三个错误。在表1中,“关键纳入标准”下的最后一行应显示为“筛查和第1天时正常或临床上可接受的ECG”。另外,表1的图例中的缩写“ IP”代表“研究产品”。
更新日期:2019-11-01
down
wechat
bug